SEOUL, Dec. 17 (Korea Bizwire) — Kakao Brain, the artificial intelligence (AI) research subsidiary of South Korean internet giant Kakao Corp., is making inroads into the global market for AI in drug discovery.
The company said Thursday that it had invested 5 billion won (US$4.21 million) in AI-based drug design platform startup Galux and established a partnership to promote joint research.
Galux is known for protein modeling technology that has swept top spots in the international protein structure prediction contests and protein interaction prediction contests held by Seoul National University over the past 10 years.
Kakao Brain plans to establish an AI-based new drug design platform by merging Galux’s drug design technology with its ultra large-sized AI model.
In addition to the establishment of the AI-based drug design platform, it will also promote the joint development of candidate materials for new drugs and digitalization of existing chemical-based experiments.
Kevin Lee (email@example.com)